CVI Holdings LLC Invests $1.44 Million in Rexahn Pharmaceuticals, Inc. (RNN)

CVI Holdings LLC acquired a new stake in shares of Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 1,547,837 shares of the company’s stock, valued at approximately $1,439,000. Rexahn Pharmaceuticals makes up about 3.2% of CVI Holdings LLC’s investment portfolio, making the stock its 7th largest position. CVI Holdings LLC owned 4.13% of Rexahn Pharmaceuticals as of its most recent SEC filing.

NYSEAMERICAN RNN opened at $0.57 on Friday. Rexahn Pharmaceuticals, Inc. has a 12-month low of $0.50 and a 12-month high of $2.38.

In other Rexahn Pharmaceuticals news, CEO Douglas J. Swirsky bought 50,000 shares of Rexahn Pharmaceuticals stock in a transaction that occurred on Tuesday, January 29th. The stock was purchased at an average price of $0.63 per share, with a total value of $31,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 50,000 shares in the company, valued at approximately $31,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders acquired 95,000 shares of company stock valued at $60,050.

A number of equities research analysts recently commented on the stock. HC Wainwright set a $17.00 target price on shares of Rexahn Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, December 6th. Zacks Investment Research cut shares of Rexahn Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 8th. Finally, Brookline Capital Management reissued a “buy” rating on shares of Rexahn Pharmaceuticals in a research report on Tuesday, November 27th. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Rexahn Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $6.25.

COPYRIGHT VIOLATION WARNING: This story was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.

Further Reading: Why is cost of goods sold important?

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with's FREE daily email newsletter.